Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P21554
UPID:
CNR1_HUMAN
Alternative names:
CANN6
Alternative UPACC:
P21554; B2R9T4; E1P512; Q13949; Q495Z0; Q4PLI4; Q4VBM6; Q5JVL5; Q5UB37; Q9UNN0
Background:
Cannabinoid receptor 1 (CNR1), also known as CANN6, is a G-protein coupled receptor primarily activated by endocannabinoids. It plays a pivotal role in regulating food intake, memory, gastrointestinal motility, and energy metabolism. CNR1's interaction with cannabinoids affects cellular respiration, mitochondrial function, and neurotransmission, showcasing its complex involvement in metabolic and neurological processes.
Therapeutic significance:
CNR1's involvement in obesity highlights its potential as a therapeutic target. Its role in diet-induced obesity, dyslipidemia, and liver steatosis suggests that modulation of CNR1 activity could offer new avenues for treating metabolic disorders. Although CNR1 inverse agonists have shown promise in reducing body weight and metabolic abnormalities, their development has been challenged by adverse effects. Further research into CNR1 could unlock novel, safer therapeutic strategies.